Process

Our Model

Origins active investment management model provides retail investors with access to the most promising opportunities.

Deal Flow

Our investment mandate is simple: focus on companies with an exemplary management team and exponential growth profile.
Estimated number of global psychedelic companies by 2022

300+

Origin performs high-level review

150

Initial due diligence including early discussions with management

60

Investment committee review

30

Management and operational due diligence

15

Negotiation

8

Investment Strategy

Our experienced team of technical and experienced investment professionals has decades of experience managing investment portfolios and have access to a diverse deal pipeline.

A time-tested due diligence process has been implemented to optimize the pipeline to filter out only the most lucrative opportunities.

We go even further by supporting the companies we invest in with advisory or board positions.

Join Our Portfolio

Companies interested in partnering with Origin Therapeutics can submit a short summary of the opportunity using the form below.